Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study

This study is a real-world observational study tracking how well the drug sacituzumab govitecan (SG) works in patients with triple-negative breast cancer (TNBC) that has spread or cannot be surgically removed. Researchers also want to identify biological markers that predict who will benefit from or tolerate this treatment best. **You may be eligible if...** - You are 18 or older - You have confirmed triple-negative breast cancer - Your cancer is locally advanced (unresectable) or metastatic - You are already being treated with sacituzumab govitecan in standard clinical practice - You have had at least two prior lines of treatment (including at least one for advanced disease) - You have tumor tissue available for analysis **You may NOT be eligible if...** - You have a history of another cancer - You have contraindications to sacituzumab govitecan - You have untreated or unstable brain metastases Talk to your doctor to see if this trial is right for you.